NICE gives Daiichi Sankyo final OK on Lixiana; India's Cipla projects 20% sales growth for the year;

@FiercePharma: Patterson shares fall on missed sales and earnings targets. FierceAnimalHealth article | Follow @FiercePharma

@EricPFierce: ICYMI: North Carolina wins Novo prize--$1.2B plant, 700 jobs as Novo builds first US, API plant. Article | Follow @EricPFierce

@CarlyHFierce: Can Sprout's Addyi shrug off serious side effects? These blockbusters did. FiercePharmaMarketing story | Follow @CarlyHFierce

> NICE in final guidance approved Daiichi Sankyo's Lixiana (edoxaban) to prevent stroke and systemic embolism in patients with non-valvular atrial fibrillation who have one or more other risk factors--such as congestive heart failure, high blood pressure or prior stroke history. Story

> Australia's Mayne Pharma has said that it expects its earnings for the year to rise, but its profit fell 64% in the year ended June 30. Story

> Boehringer Ingelheim has added to its board of directors. Release

> Novartis ($NVS) India Friday said regulators had approved the sale of its consumer health unit there to GlaxoSmithKline ($GSK), part of the multibillion asset swap the two announced last year. Report

> India's Cipla today said it is forecasting a 20% rise in revenue in fiscal 2016. Story

Medical Device News

@FierceMedDev: FDA scolds Cepheid for manufacturing issues in Sweden. FierceDiagnostics story | Follow @FierceMedDev

@VarunSaxena2: Updated $ABT's interest in $STJ w/ info from old article on their prior partnership. Neat to add context from 2012. Article | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: J&J and PCH launch hardware startup accelerator. Story | Follow @EmilyWFierce

> Nerve repair micro-cap AxoGen nabs $17.5M from PE group to get to cash-flow positive. More

> Recall roundup: CareFusion infusion pump, J&J sedation device, Teleflex endobronchial tube. Story

> DOD chips in for $171M Silicon Valley flexible electronics project. Article

Biotech News

@FierceBiotech: UPDATED: Amgen gets a big win with FDA OK for PCSK9 cholesterol drug. Article | Follow @FierceBiotech

@JohnCFierce: Eli Lilly's marginal cancer drug becomes Exhibit A in pricing dilemma. Report | Follow @JohnCFierce

> Stem cell researcher cleared of misconduct after U-turn. Story

> Novo Nordisk buys diabetes startups founded by Lilly R&D veteran. Report

> The FDA offers a controversial solution to the biosimilars name game. Article

Suggested Articles

Novartis said it plans to use the complete response rate data for a U.S. filing in follicular lymphoma in 2021.

Sen. Elizabeth Warren asked the SEC to probe Kodak trades made before the Trump administration unveiled their drug supply deal—and $765M in funding.

Amarin's wild 2020 ride continues with plans to launch its cardiovascular med Vascepa in Europe without a bigger marketing partner.